The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).
 
Michael Geissler
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen
 
Jorge Riera-Knorrenschild
No Relationships to Disclose
 
Andrea Tannapfel
No Relationships to Disclose
 
Jobst Greeve
No Relationships to Disclose
 
Axel Florschütz
No Relationships to Disclose
 
Swen Wessendorf
No Relationships to Disclose
 
Thomas Seufferlein
No Relationships to Disclose
 
Stephan Kanzler
No Relationships to Disclose
 
Swantje Held
No Relationships to Disclose
 
Volker Heinemann
Honoraria - Amgen; Baxalta; Celgene; Merck; Roche; Sanofi; Sirtex Medical
Consulting or Advisory Role - Amgen; Baxalta; Boehringer Ingelheim; Celgene; Merck; Roche; Sanofi; Sirtex Medical
Research Funding - Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); IntegraGen (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst); Sirtex Medical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Baxalta; Merck; Roche; Sirtex Medical
 
Anke C. Reinacher-Schick
No Relationships to Disclose
 
Uwe Marc Martens
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; MSD Oncology; Roche
Travel, Accommodations, Expenses - Amgen